Home
About
About Anagenics
Board of Directors
Divisions
Our Divisions
Beauty
Brands
évolis®
Uspa
Investors
Investor Centre
ASX Announcements
2024
2023
2022
2021
2020
2019
Financial Information & Reports
Share Registry Information
Analyst Coverage
Share Information
Anagenics in the media
Newsletter Archive
Corporate Governance
Corporate Governance
Board Charter
Code of Conduct
Policies
Audit Committee Charter
Nomination and Remuneration Committee Charter
Performance Evaluation Process
Corporate Code of Conduct
Environmental, Social and Governance Statement
✕
2019
Home
2019
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Appendix 4C and Notes to Appendix 4C
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Significant New Findings Published On MIDKINE
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Appendix 4D, Half Year Accounts and Strategy Update
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Minimum Holding Share Buy-Back
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid Investor Newsletter March 2019
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid Alopecia Patent allowed in Europe
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Repayment of Cellmid loan issued to Director pursuant to employee incentive plan
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid notes to the Appendix 4C
November 11, 2019
Published by
Tiffany McMillan
on
November 11, 2019
Categories
Cellmid’s evolis registered in European Union
Prev page
1
2
3
4
5
6
Next page
